"Biological Products" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Complex pharmaceutical substances, preparations, or matter derived from organisms usually obtained by biological methods or assay.
| Descriptor ID |
D001688
|
| MeSH Number(s) |
D20.215
|
| Concept/Terms |
Biological Products- Biological Products
- Biologic Products
- Products, Biologic
- Biologics
- Products, Biological
|
Below are MeSH descriptors whose meaning is more general than "Biological Products".
Below are MeSH descriptors whose meaning is more specific than "Biological Products".
This graph shows the total number of publications written about "Biological Products" by people in this website by year, and whether "Biological Products" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biological Products" by people in Profiles.
-
Associations between accelerated parental biologic age, autism spectrum disorder, social traits, and developmental and cognitive outcomes in their children. Autism Res. 2022 12; 15(12):2359-2370.
-
An Observational Study of Cardiovascular Risks Associated with Rheumatoid Arthritis Therapies: A Comparison of Two Analytical Approaches. Perm J. 2018; 22:17-101.
-
Comparative Effectiveness of Etanercept and Adalimumab in Patient Reported Outcomes and Injection-Related Tolerability. PLoS One. 2016; 11(3):e0149781.
-
Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study. Ann Rheum Dis. 2014 Nov; 73(11):1942-8.
-
Initiation of tumor necrosis factor a antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases. Arthritis Care Res (Hoboken). 2013 Jul; 65(7):1085-94.
-
Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiol Drug Saf. 2012 Jan; 21 Suppl 1:23-31.
-
Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems. Pharmacoepidemiol Drug Saf. 2011 Nov; 20(11):1199-209.
-
Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals. Regul Toxicol Pharmacol. 2010 Nov; 58(2):243-51.
-
Privacy-maintaining propensity score-based pooling of multiple databases applied to a study of biologics. Med Care. 2010 Jun; 48(6 Suppl):S83-9.